Status:
COMPLETED
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
Lead Sponsor:
Foresee Pharmaceuticals Co., Ltd.
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with prostate cancer, when administered as two injections twelve weeks apart.
Detailed Description
This is a multi-national, multi-center, open-label, single-arm study. All subjects will be males with prostate cancer judged to be candidates for medical androgen ablation therapy and all will receive...
Eligibility Criteria
Inclusion
- Males aged ≥ 18 years old
- Males with histologically confirmed carcinoma of the prostate
- Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy
- Baseline morning serum testosterone level \> 150 ng/dL performed at Screening Visit
- Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2
- Life expectancy of at least 18 months
- Laboratory values
- Absolute neutrophil count ≥ 1,500 cells/µL
- Platelets ≥ 100,000 cells/µL
- Hemoglobin ≥ 10 gm/dL
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- AST (SGOT) ≤ 2.5 × ULN
- ALT (SGPT) ≤ 2.5 × ULN
- Serum creatinine ≤ 1.5 mg/dL
- Lipid profile within acceptable range according to investigator's opinion
- Serum glucose within acceptable range according to investigator's opinion
- HgbA1c within acceptable range according to investigator's opinion
- Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
- Serum glucose within acceptable range according to investigator's judgement
- Urinalysis within normal range according to the investigator's judgment
- Agree to use male contraceptive methods during study trial
- Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
- All aspects of the protocol explained and written informed consent obtained
Exclusion
- Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
- Receipt of any vaccination (including influenza) within 4 weeks of screening visit
- History of blood donation within 2 months of screening visit
- History of anaphylaxis to any LH-RH analogues
- Receipt of any LHRH suppressive therapy within 6 months of screening visit
- Major surgery, including any prostatic surgery, within 4 weeks of screening visit
- History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases and subjects at risk for spinal cord compression
- Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
- History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
- History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
- Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator
- History of drug and/or alcohol abuse within 6 months of Baseline
- Contraindication to leuprolide or an LHRH agonist as indicated on package labeling
- Use of 5-alpha reductase inhibitor within the last 6 months of screening visit
- History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed if only oral hypoglycemic are required. Prostate cancer subjects with poor controlled diabetes mellitus with Hb1Ac \> 9.5% or urine glycosuria \> 1.0 g/dL should be excluded.
- Use of systemic corticosteroids at a dose \>10 mg/d or anti-androgens
- Use of any investigational agent within 4 weeks of screening visit
- Use of any over-the-counter (OTC) medication within 4 weeks of screening visit except for those listed in the permitted Concomitant Treatment section.
- Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor
Key Trial Info
Start Date :
September 26 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2019
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT03261999
Start Date
September 26 2017
End Date
February 1 2019
Last Update
May 4 2020
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Centers of Alabama
Homewood, Alabama, United States, 35209
2
Arizona Institute of Urology
Tucson, Arizona, United States, 85704
3
The Urology Center of Colorado
Denver, Colorado, United States, 80211
4
Carolina Clinical Trials, LLC
Concord, North Carolina, United States, 28025